<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619630</url>
  </required_header>
  <id_info>
    <org_study_id>AOM12629_2</org_study_id>
    <nct_id>NCT02619630</nct_id>
  </id_info>
  <brief_title>Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)</brief_title>
  <acronym>GRAALL-2014/T</acronym>
  <official_title>Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of nelarabine-based consolidation and
      maintenance therapy in term of relapse-free survival (RFS) in high-risk (HR) patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality (NRM)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival censored at allograft in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse censored at allograft in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival censored at allograft in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality (NRM) censored at allograft in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD)</measure>
    <time_frame>within 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having received the 5 cycles of nelarabine</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>T-cell Adult Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>High-Risk (HR) patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nelarabine during consolidation and maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nelarabine</intervention_name>
    <description>Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil &gt;1 Giga/Liter
for a maximum of 5 blocks</description>
    <arm_group_label>High-Risk (HR) patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Whose blood and bone marrow explorations have been completed before the steroids
             prephase

          2. aged 18-59 years old with a not previously treated (including IT injection) T-ALL
             newly-diagnosed according to the WHO 2008 definition with &gt; 20% bone marrow blasts

          3. With Eastern Cooperative Oncology Group (ECOG) performance status &lt; 3

          4. With or without central nervous system (CNS) involvement or testis

          5. Without other evolving cancer (except basal cell carcinoma of the skin and &quot;in situ&quot;
             carcinoma of the cervix) or its chemo or radio-therapy treatment finished at least
             since 6 months

          6. Having signed a written informed consent

          7. With efficient contraception for women of childbearing age (excluding estrogens and
             IUD)

          8. Having received or being receiving steroid prephase

          9. With health insurance coverage

        Exclusion Criteria:

          1. With lymphoblastic lymphoma and bone marrow blasts &lt; 20%, Burkitt-type ALL or with
             antecedents of chronic myeloid leukemia (CML) or other myeloproliferative neoplasm

          2. With contra-indication to anthracyclines or any other general or visceral
             contra-indication to intensive therapy except if considered related to the ALL:

               -  Aspartate transaminase (AST) and/or alanine transaminase (ALT) &gt; 5 x upper limit
                  of normal range (ULN)

               -  Total bilirubin ≥ 2.5 x upper limit of normal range (ULN)

               -  Creatinine &gt; 1.5 x upper limit of normal range (ULN) or creatinine clearance &lt;50
                  mL/mn

          3. Myocardial infarction within 6 months prior to inclusion in the trial, cardiomyopathy
             (NYHA grade III or IV), left ejection ventricle fraction (LEVF) &lt; 50% and/or RF &lt; 30%,

          4. Active severe infection or known seropositivity for HIV or Human T cell
             leukemia/lymphoma virus type 1 (HTLV-1) or active hepatitis B or C

          5. Other active malignancy

          6. Pregnant (beta-Human Chorionic Gonadotropin (hCG) positive) or nursing woman

          7. Women of childbearing potential not willing to use an effective form of contraception
             during participation in the study and at least three months thereafter. Patients not
             willing to ensure not to beget a child during participation in the study and at least
             three months thereafter

          8. Treated with any other investigational agent or participation in another trial within
             30 days prior to entering this study

          9. Not able to bear with the procedures or the frequency of visits planned in the trial

         10. Unable to consent, under tutelage or curators, or judiciary safeguard
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hervé Dombret, MDPhD</last_name>
    <phone>+33 (0)1 57 27 68 47</phone>
    <email>herve.dombret@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique Lhéritier</last_name>
    <phone>+33(0)4 78 86 22 39</phone>
    <email>veronique.lheritier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Dombret, MDPhD</last_name>
      <email>herve.dombret@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

